; and (B) by striking clause (iv) and inserting the following: (iv) For each of fiscal years 2021, 2022, and 2023, $50,000,000. (v) For each of fiscal years 2024 through 2030, $10,000,000. ; and (6) by adding at the end the following: (E) To support research related to combating antimicrobial resistance and antibiotic resistant bacteria, not to exceed a total of $1,635,000,000, as follows: (i) For fiscal year 2021, $100,000,000. (ii) For each of fiscal years 2022 through 2024, $150,000,000. (iii) For each of fiscal years 2025 through 2027, $175,000,000. (iv) For each of fiscal years 2028 and 2029, $180,000,000. (v) For fiscal year 2030, $200,000,000. (F) To support research and research activities related to rare diseases or conditions, not to exceed a total of $758,000,000, as follows: (i) For fiscal year 2021, $50,000,000. (ii) For fiscal year 2022, $55,000,000. (iii) For fiscal year 2023, $60,000,000. (iv) For fiscal year 2024, $65,000,000. (v) For fiscal year 2025, $70,000,000. (vi) For fiscal year 2026, $75,000,000. (vii) For fiscal year 2027, $80,000,000. (viii) For fiscal year 2028, $90,000,000. (ix) For fiscal year 2029, $100,000,000. (x) For fiscal year 2030, $113,000,000. . (e) Workplan Section 1001(c)(1)(A) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking 2026 and inserting 2030 . (f) Recommendations Section 1001(c)(1)(C)(i) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking 2026 and inserting 2030 . (g) Annual reports Section 1001(c)(2)(A) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking 2027 and inserting 2030 . (h) Sunset Section 1001(e) of the 21st Century Cures Act ( Public Law 114–255 ) is amended by striking September 30, 2026 and inserting September 30, 2030 .